No matches
Pulmonology

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.
Zuzana Diamant
MD, PhD
Zuzana Diamant

Related resources

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

expert video
Compounded Burden of Co-existing Type 2 Airway Diseases

Compounded Burden of Co-existing Type 2 Airway Diseases

expert video
Type 2 Inflammation Underpins Pediatric Severe Asthma

Type 2 Inflammation Underpins Pediatric Severe Asthma

Infographic
ERS 2023 | Adult Asthma Symposium: Mini Debate

ERS 2023 | Adult Asthma Symposium: Mini Debate

expert video
IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

expert video
ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

expert video
COPD and Asthma: What's the Difference and Is There a Link?

COPD and Asthma: What's the Difference and Is There a Link?

interactivity
ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

expert video
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

Infographic
The Cycle of Inflammation in Adult Asthma

The Cycle of Inflammation in Adult Asthma

interactivity
ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management

ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management

expert video
IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

expert video
What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

expert video
ERS 2024 | IL-33 A Promising Target

ERS 2024 | IL-33 A Promising Target

expert video
FeNO as a Biomarker for Type 2 Asthma

FeNO as a Biomarker for Type 2 Asthma

expert video
ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?

ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?

expert video
IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

expert video
How does a decrease in smell affect sleep disturbance? Is there any direct relation?

How does a decrease in smell affect sleep disturbance? Is there any direct relation?

expert video
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

expert video
ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

ERS 2024 | View From the Clinic: What Are the Clinical Consequences of Airway Remodeling?

expert video
ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?

expert video
IgE as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma

expert video
ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

expert video
IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

expert video
Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

expert video
ERS 2024 | Can Biologics Affect Airway Remodeling?

ERS 2024 | Can Biologics Affect Airway Remodeling?

expert video
ADVENT On Air | Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma

ADVENT On Air | Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma

Podcast
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions

ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions

expert video
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

expert video
ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

expert video
IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

expert video
When is the right time to consider a biologic in patients with CRSwNP?

When is the right time to consider a biologic in patients with CRSwNP?

expert video
ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?

ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?

expert video
How Can FeNO Measurement Improve Severe Asthma Management?

How Can FeNO Measurement Improve Severe Asthma Management?

expert video
Screen depicting a mucus plug in the airways

A view into the Airway: The Pathophysiology and Clinical Relevance of Mucus Plugs in Asthma

videoanimation
Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

expert video
ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

expert video
IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

expert video
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

expert video
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

expert video

Learning objectives

  • To highlight efficacy data in patients with severe/uncontrolled CRSwNP and co-existing asthma from biologic studies
Tags
quality of lifeairway remodelingexpert insightssymposiummechanism of diseasetype 2 inflammationasthmaCRSwNP
MAT-GLB-2505226 - 1.0 - 09/2025

About this expert

Allergy/Immunology

Zuzana Diamant

MD, PhD

Zuzana Diamant is a pulmonologist and clinical pharmacologist. She is currently a Guest Professor at KUL, Leuven, Belgium. Prof. Diamant also holds the position of Research Director Respiratory & Allergy at QPS-Netherlands, Groningen, Netherlands.

See author’s profile
Zuzana Diamant

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: NorwayChange country/region